Back to results
US 2022/0175700 A1Published application
Visual cycle modulators
AssigneeCase Western Reserve University
InventorsKrzysztof Palczewski, Philip Kiser, Jianye Zhang, Mohsen Badiee, Gregory Tochtrop
Life of this patent
Estimating the term…
Abstract
A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).
Claims28
A method of treating an ocular disorder in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I):
- wherein n1 is an integer from 1 to 6;
- R1 is H or a lipophilic or hydrophobic alkyl or fluoro alkyl group that includes at least three carbon atoms;
- R2 is H, CH3, or OH;
- R3 is a substituted or unsubstituted C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C6 aryl, heteroaryl, heterocyclyl, or C6-C12 alkaryl, wherein R3 is not a substituted or unsubstituted cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, or branched alkyl if R1 is H and n1 is 1;
- the dashed line is an optional bond;
- and
- pharmaceutically acceptable salts thereof.
5 more elements
A method of treating an ocular disorder in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (II):
- wherein n1 is an integer from 1 to 6;
- R1 is a lipophilic or hydrophobic alkyl or fluoroalkyl group that includes at least three carbon atoms and is branched and/or cyclic;
- R2 is H, CH3, or OH;
- R3 is a substituted or unsubstituted C1-C12, alkyl, C2-C12 alkenyl, C2-C12 alkynyl, C3-C6 aryl, heteroaryl, heterocyclyl, or C6-C12 alkaryl;
- the dashed line is an optional bond;
- and
- pharmaceutically acceptable salts thereof.
5 more elements
Dependencies are inferred from the claim text.